These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35366419)

  • 21. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
    Vermeire S; Sands BE; Tilg H; Tulassay Z; Kempinski R; Danese S; Bunganič I; Nitcheu J; Santo J; Scherrer D; Biguenet S; Ehrlich HJ; Steens JM; Gineste P; Sandborn WJ
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1024-1035. PubMed ID: 36075249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
    Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
    Paramsothy S; Kamm MA; Kaakoush NO; Walsh AJ; van den Bogaerde J; Samuel D; Leong RWL; Connor S; Ng W; Paramsothy R; Xuan W; Lin E; Mitchell HM; Borody TJ
    Lancet; 2017 Mar; 389(10075):1218-1228. PubMed ID: 28214091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Choy MC; Li Wai Suen CFD; Con D; Boyd K; Pena R; Burrell K; Rosella O; Proud D; Brouwer R; Gorelik A; Liew D; Connell WR; Wright EK; Taylor KM; Pudipeddi A; Sawers M; Christensen B; Ng W; Begun J; Radford-Smith G; Garg M; Martin N; van Langenberg DR; Ding NS; Beswick L; Leong RW; Sparrow MP; De Cruz P
    Lancet Gastroenterol Hepatol; 2024 Nov; 9(11):981-996. PubMed ID: 39236736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
    Louis E; Schreiber S; Panaccione R; Bossuyt P; Biedermann L; Colombel JF; Parkes G; Peyrin-Biroulet L; D'Haens G; Hisamatsu T; Siegmund B; Wu K; Boland BS; Melmed GY; Armuzzi A; Levine P; Kalabic J; Chen S; Cheng L; Shu L; Duan WR; Pivorunas V; Sanchez Gonzalez Y; D'Cunha R; Neimark E; Wallace K; Atreya R; Ferrante M; Loftus EV;
    JAMA; 2024 Sep; 332(11):881-897. PubMed ID: 39037800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
    N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
    Peyrin-Biroulet L; Allegretti JR; Rubin DT; Bressler B; Germinaro M; Huang KG; Shipitofsky N; Zhang H; Wilson R; Han C; Feagan BG; Sandborn WJ; Panés J; Hisamatsu T; Lichtenstein GR; Sands BE; Dignass A;
    Gastroenterology; 2023 Dec; 165(6):1443-1457. PubMed ID: 37659673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
    Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate for induction of remission in ulcerative colitis.
    Chande N; Wang Y; MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006618. PubMed ID: 25162749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
    Sandborn WJ; Bhandari BR; Randall C; Younes ZH; Romanczyk T; Xin Y; Wendt E; Chai H; McKevitt M; Zhao S; Sundy JS; Keshav S; Danese S
    J Crohns Colitis; 2018 Aug; 12(9):1021-1029. PubMed ID: 29767728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
    Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
    Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.
    Fukase H; Kajioka T; Oikawa I; Ikeda N; Furuie H
    Br J Clin Pharmacol; 2020 Mar; 86(3):591-600. PubMed ID: 31658381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.